Contact Us
Drug Search Results
More Filters [+]

Caspofungin

Alternative Names: caspofungin, CASPOFUNGINA, cancidas
Latest Update: 2024-08-21
Latest Update Note: Clinical Trial Update

Product Description

Caspofungin injection is used in adults and children 3 months of age and older to treat yeast infections in the blood, stomach, lungs, and esophagus (tube that connects the throat to the stomach.) and certain fungal infections that could not be treated successfully with other medications. (Sourced from: https://medlineplus.gov/druginfo/meds/a615001.html)

Mechanisms of Action: Glucan Synthase Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Abdominal Abscess | Abscess | Candidemia | Peritonitis | Aspergillosis | Candidiasis | Candidiasis, Invasive | Invasive Fungal Infections

Known Adverse Events: Hypotension | Chills | Diarrhea

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Caspofungin

Countries in Clinic: China, South Africa, Unknown Location

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Candidemia|Candidiasis, Invasive|Candidiasis, Oral

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20223058

P3

Not yet recruiting

Candidiasis, Oral|Candidemia|Candidiasis, Invasive

None

Recent News Events

Date

Type

Title

05/23/2024

News Article

 Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris

04/30/2024

News Article

 SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

02/12/2024

News Article

 Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

01/29/2024

News Article

 Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions